Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?

Sara Pagani, Eduardo A. Chaler, Cristina Meazza, Mercedes Maceiras, Maria Eugenia Gonzalez, Marco A. Rivarola, Francesca Cantoni, Paola Travaglino, Lucia Delia Croce, Kamilia Laarej, Mauro Bozzola, Alicia Belgorosky

Research output: Contribution to journalArticlepeer-review


We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.

Original languageEnglish
Pages (from-to)783-788
Number of pages6
JournalJournal of Pediatric Endocrinology and Metabolism
Issue number8
Publication statusPublished - Aug 2010


  • Bioassay
  • Cell line
  • Gene mutation
  • GH biological activity
  • Growth hormone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?'. Together they form a unique fingerprint.

Cite this